GARZINO DEMO, ALFREDO
 Distribuzione geografica
Continente #
NA - Nord America 221
EU - Europa 64
AS - Asia 27
AF - Africa 2
OC - Oceania 1
SA - Sud America 1
Totale 316
Nazione #
US - Stati Uniti d'America 217
DE - Germania 20
IT - Italia 17
FR - Francia 15
CN - Cina 11
AE - Emirati Arabi Uniti 4
CA - Canada 4
HK - Hong Kong 4
IN - India 4
FI - Finlandia 3
NL - Olanda 3
GB - Regno Unito 2
RU - Federazione Russa 2
AU - Australia 1
CL - Cile 1
EG - Egitto 1
ES - Italia 1
IQ - Iraq 1
IS - Islanda 1
JP - Giappone 1
KE - Kenya 1
MO - Macao, regione amministrativa speciale della Cina 1
SG - Singapore 1
Totale 316
Città #
Fairfield 30
Seattle 20
Padova 14
Santa Cruz 14
Buffalo 13
Cambridge 13
Woodbridge 12
Ashburn 9
Houston 8
Chicago 6
Los Angeles 6
San Diego 6
Wilmington 6
Des Moines 4
Phoenix 4
Ann Arbor 3
Dallas 3
Shanghai 3
Aberdeen 2
Beijing 2
Helsinki 2
High Point 2
Saint Petersburg 2
Tianjin 2
Toronto 2
University Park 2
Amsterdam 1
Bengaluru 1
Birmingham 1
Brighton 1
Cheyenne 1
Clearwater 1
Columbus 1
Easton 1
Erbil 1
Esslingen am Neckar 1
Falkenstein 1
Frankfurt Am Main 1
Hamilton 1
Hangzhou 1
Henderson 1
Kingston 1
Lake Forest 1
Lappeenranta 1
Las Vegas 1
Lincoln 1
Melbourne 1
Milpitas 1
Mysore 1
Nairobi 1
New York 1
Orlando 1
Osaka 1
Ottawa 1
Paris 1
Provo 1
Queens 1
Reggio Nell'emilia 1
Reykjavik 1
Riva 1
Secaucus 1
Singapore 1
Stow 1
Taizhou 1
Vicenza 1
Zaragoza 1
Totale 230
Nome #
The θ-defensin retrocyclin 101 inhibits TLR4- and TLR2-dependent signaling and protects mice against influenza infection, file e14fb269-e0bc-3de1-e053-1705fe0ac030 132
Human beta defensin 2 selectively inhibits HIV-1 in highly permissive CCR6+CD4+ T cells, file e14fb269-e61d-3de1-e053-1705fe0ac030 104
Celastrol, a Chinese herbal compound, controls autoimmune inflammation by altering the balance of pathogenic and regulatory T cells in the target organ, file e14fb26f-9a6a-3de1-e053-1705fe0ac030 23
Mechanism through which retrocyclin targets flavivirus multiplication, file e14fb26e-e603-3de1-e053-1705fe0ac030 14
Human Beta-Defensin 2 and 3 Inhibit HIV-1 Replication in Macrophages, file e14fb26f-1628-3de1-e053-1705fe0ac030 9
HIV-Associated Interactions Between Oral Microbiota and Mucosal Immune Cells: Knowledge Gaps and Future Directions, file e14fb26f-180b-3de1-e053-1705fe0ac030 8
The G-quadruplex-forming aptamer AS1411 potently inhibits HIV-1 attachment to the host cell, file e14fb268-a115-3de1-e053-1705fe0ac030 7
Expression of HIV-1 matrix protein p17 and association with B-cell lymphoma in HIV-1 transgenic mice, file e14fb268-f35d-3de1-e053-1705fe0ac030 7
Decreased MIP-3α production from antigen-activated PBMCs in symptomatic HIV-infected subjects, file e14fb26f-5ed2-3de1-e053-1705fe0ac030 6
Editorial: Novel Insights Into a Functional HIV Cure, file e14fb26f-8e64-3de1-e053-1705fe0ac030 4
Persistent and transient olfactory deficits in COVID-19 are associated to inflammation and zinc homeostasis, file 545c077e-7713-4ed1-87cb-ca3202ee2d5f 3
Elevated suppressor of cytokine signaling-1 (SOCS-1): a mechanism for dysregulated osteoclastogenesis in HIV transgenic rats, file e14fb268-f021-3de1-e053-1705fe0ac030 3
Highly active antiretroviral therapy reduces pulmonary IL-8 in HIV-positive women smokers, file e14fb268-f780-3de1-e053-1705fe0ac030 3
Fresh faces and new approaches at Pathogens and Disease, file e14fb26c-4527-3de1-e053-1705fe0ac030 2
Angiogenic, lymphangiogenic and adipogenic effects of HIV-1 matrix protein p17, file e14fb268-f031-3de1-e053-1705fe0ac030 1
HIV-associated lymphoma in the era of combination antiretroviral therapy: shifting the immunological landscape, file e14fb268-f36e-3de1-e053-1705fe0ac030 1
Human beta defensin 2 selectively inhibits HIV-1 in highly permissive CCR6+CD4+ T cells, file e14fb269-e7a0-3de1-e053-1705fe0ac030 1
New targets for HIV drug discovery, file e14fb26c-4529-3de1-e053-1705fe0ac030 1
Totale 329
Categoria #
all - tutte 1.336
article - articoli 1.336
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 2.672


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/201937 0 0 0 0 0 0 0 0 0 0 26 11
2019/202060 7 9 1 5 5 4 6 4 6 7 2 4
2020/202131 1 5 1 2 0 2 1 3 8 2 5 1
2021/202260 3 7 1 5 4 1 5 5 1 2 19 7
2022/202359 4 7 13 6 8 5 3 0 1 7 4 1
2023/202450 0 0 1 3 0 10 2 7 18 5 4 0
Totale 329